Brief: Vertex Announces Key Advancements Across Kidney Portfolio
25/09/2025 13:28
Sept 25 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES KEY ADVANCEMENTS ACROSS KIDNEY PORTFOLIO VERTEX PHARMACEUTICALS INC: FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR POVETACICEPT IN IGA NEPHROPATHY VERTEX PHARMACEUTICALS INC - ON TRACK TO FILE FOR ACCELERATED APPROVAL IN U.S. IN H1 2026 Source text: ID:nBw9fmr9na Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria